Accessibility Menu
Dyadic International logo

Dyadic International(NASDAQ) DYAI

Current Price$1.21
Market Cap$43.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-79%
5 Year-67%
1 Year+6%
1 Month+63%
Dyadic International last closing stock price
MetricPriceDate
Last closeUSD 1.192026-07-24
Dyadic International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.56%USD 1.262026-07-17
1 month+62.79%USD 0.732026-06-24
3 month+38.37%USD 0.862026-04-24
Year to date+26.6%USD 0.942025-12-31
1 year+6.25%USD 1.122025-07-24
3 year-34.97%USD 1.832023-07-25
5 year-66.67%USD 3.572021-07-23
Since inception-79.2%USD 6.252004-11-05

Dyadic International Financials at a Glance

Market Cap

$43.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.97M

Net Income (TTM)

-$7.29M

EPS (TTM)

-$0.21

P/E Ratio

-5.56

Dividend

$0.00

Beta (Volatility)

0.81 (Low)

Price

$1.21

Volume

665

Open

$1.15

Previous Close

$1.21

Daily Range

$1.15 - $1.21

52-Week Range

$0.65 - $1.60

Estimated Earnings Date

Aug 12, 2026

DYAI News

featured-earnings-leadership-highlights.png

Dyadic International Narrows Q2 Loss

Motley Fool Markets TeamAug 13, 2025
Foolcom-Featured.png

Dyadic Revenue Jumps 150% in Fiscal Q2

Motley Fool Markets TeamAug 13, 2025
GettyImages-823447656

This Revolutionary Biotech Is Shrouded in Mystery. Is It a Buy?

Zhiyuan SunJun 24, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dyadic International

Dyadic makes proteins and enzymes used in vaccines, food, and industrial products. Its technology helps companies create animal-free ingredients for medicines and nutrition. These products support safer drugs and more sustainable food options for manufacturers and researchers.

Products and Services

  • Recombinant Proteins: Animal-free proteins for medicines, diagnostics, and research; main buyers are pharmaceutical and biotech firms.
  • Enzyme Solutions: Enzymes for food processing, nutrition, and industrial uses; targets food producers and bio-industrial companies.
  • Protein Production Platforms: C1 and Dapibus systems for scalable, low-cost protein manufacturing; licensed to partners and used in-house.
  • Research and Development Services: Custom protein and enzyme development for clients; revenue share not specified.
  • Licensing and Milestone Payments: Income from technology licensing and development milestones; 8.6% of 2025 revenue.

Growth and Expansion

  • Launched AlbuFree DX with Proliant Health in 2026 for animal-free albumin.
  • Introduced recombinant DNase I with Fermbox Bio in March 2026.
  • Expanded partnership with Fermbox Bio for new protein and enzyme products in 2025-2026.
  • Signed development agreement with BRIG BIO for bovine alpha-lactalbumin in 2025.
  • Received grants from the Gates Foundation and CEPI for vaccine and antibody platform validation in 2025.

What Makes Dyadic Stand Out

Dyadic’s platforms allow for animal-free, scalable protein production, supporting sustainability trends. Its flexible business model includes direct sales, licensing, and research partnerships. The company’s technology is validated by global health organizations and industry collaborations.

Five Things You Need to Know

  • Revenue was $3.1 million in 2025, down 11.6% from 2024.
  • Net loss was $7.4 million in 2025, up 26.8% from 2024.
  • Two customers made up 60.1% of 2025 revenue.
  • Cash and investments totaled $8.6 million at December 31, 2025.
  • Convertible notes outstanding were $5 million at year-end 2025.

Bottom Line

Dyadic has evolved through partnerships, new product launches, and grant funding. Its focus on animal-free proteins and flexible commercialization supports adaptability in a competitive market.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Mark A. Emalfarb

Website

www.dyadic.com

Headquarters

Jupiter, FL 33477-5094, US

DYAI Financials

Key Financial Metrics (TTM)

Gross Margin

31.26%

Operating Margin

-238.40%

Net Income Margin

-245.12%

Return on Equity

-1004.96%

Return on Capital

-113.55%

Return on Assets

-93.37%

Earnings Yield

-17.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$43.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.44M

Volume

665

Avg. Volume

330.30K

Financials (TTM)

Gross Profit

$929.95K

Operating Income

-$7.09M

EBITDA

-$6.85M

Operating Cash Flow

-$5.72M

Capital Expenditure

$8.00

Free Cash Flow

-$5.72M

Cash & ST Invst.

$6.52M

Total Debt

$5.05M

Dyadic International Performance Analysis

Dyadic International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,930,30321.9%
20232023-12-31USD 2,898,806-1.1%
20242024-12-31USD 3,495,38920.6%
20252025-12-31USD 3,090,345-11.6%
Dyadic International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30153.1%
Q32025-09-30151.3%
Q42025-12-31-79.8%
Q12026-03-31371.3%
Dyadic International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.34-26.9%
20232023-12-31USD -0.24-31.2%
20242024-12-31USD -0.20-16.1%
20252025-12-31USD -0.2313.9%
Dyadic International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3012.1%
Q32025-09-30-0.7%
Q42025-12-3127.8%
Q12026-03-31-15.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.11M

+506.7%

Gross Profit

$319.12K

+378.6%

Gross Margin

28.72%

N/A

Market Cap

$43.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.67M

N/A

Employees

5

N/A

Net Income

-$1.95M

+3.6%

EBITDA

-$1.85M

+3.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.52M

-11.3%

Total Debt

$5.05M

-0.2%

Accounts Receivable

$1.01M

+355.0%

Inventory

$0.00

N/A

Long Term Debt

$5.03M

+0.5%

Short Term Debt

$20.00K

-64.2%

Return on Assets

-93.37%

N/A

Return on Invested Capital

-1.53%

N/A

Free Cash Flow

-$1.96M

-0.7%

Operating Cash Flow

-$1.96M

-0.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATHEAlterity Therapeutics Limited
$4.54-3.20%
ELUTElutia Inc
$0.93-0.27%
PYPDPolyPid Ltd.
$3.90-8.02%
VERUVeru Inc.
$2.25-2.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
SOFISoFi Technologies
$16.46-0.01%

Questions About DYAI

What is the current price of Dyadic International?

Dyadic International is trading at $1.21 per share.

What is the 52-week range for Dyadic International?

Over the past 52 weeks, Dyadic International has traded between $0.65 and $1.60.

How much debt does Dyadic International have?

As of the most recent reporting period, Dyadic International reported total debt of $5.05M.

How much cash does Dyadic International have on hand?

Dyadic International reported $5.16M in cash and cash equivalents in its most recent financial results.

What is Dyadic International’s dividend yield?

Dyadic International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services